SCHEMBL2789163

SCHEMBL2789163

O=C(O[C@@H]1CCCC[C@H]1OC(=O)c1cc(O)c(O)c(O)c1)c1cc(O)c(O)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SERPINE1 P05121 5/20 1.00
▸ SYNJ2 O15056 1/20 0.55
▸ DYRK1A Q13627 6/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ PRKCG P05129 1/20 0.52
▸ PRKCB P05771 1/20 0.52
▸ PRKCA P17252 1/20 0.52
▸ PRKCH P24723 1/20 0.52
▸ PRKCI P41743 1/20 0.52
▸ PRKCE Q02156 1/20 0.52
▸ PRKCQ Q04759 1/20 0.52
▸ PRKCZ Q05513 1/20 0.52
▸ PRKCD Q05655 1/20 0.52
▸ PRKD1 Q15139 1/20 0.52
▸ KDM4E B2RXH2 3/20 0.50
▸ TDP1 Q9NUW8 3/20 0.50
▸ POLB P06746 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ FUT7 Q11130 2/20 0.50
▸ LMNA P02545 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2790213 1.00 SERPINE1 (1.00) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL15069951 1.00 SERPINE1 (1.00) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL15052516 0.96 SERPINE1 (0.93) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL3654334 0.92 SERPINE1 (0.86) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL12120882 0.92 SERPINE1 (0.84) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL10016123 0.92 SERPINE1 (0.84) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL10016129 0.91 SERPINE1 (0.82) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL157443 0.85 SERPINE1 (0.86) SERPINE1SYNJ2DYRK1APRKD3PRKCG
SCHEMBL28457118 0.84 SERPINE1 (0.83) SERPINE1DYRK1APRKD3PRKCGPRKCB
SCHEMBL28462463 0.84 SERPINE1 (0.83) SERPINE1DYRK1APRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2794030-B1 COMPOSITIONS COMPRISING GALLATES AND GALLAMIDES COLGATE PALMOLIVE CO (US) 2017-03-15 — — EP claimed
CN-110506044-B BRD4 inhibitor and preparation and application thereof 中国科学院上海药物研究所 2022-07-05 — — CN disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 — — US disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 — — US disclosed
US-9527878-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-12-27 — — US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 — — US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 — — US disclosed
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2016-01-14 — — US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 — — US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 — — US disclosed
US-9120744-B2 Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2015-09-01 — — US disclosed
US-20130164228-A1 COMPOSITIONS COMPRISING GALLATES AND GALLAMIDES COLGATE-PALMOLIVE COMPANY (US) 2013-06-27 — — US disclosed
US-20130164228-A1 COMPOSITIONS COMPRISING GALLATES AND GALLAMIDES COLGATE-PALMOLIVE COMPANY (US) 2013-06-27 — — US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 — — US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 — — US disclosed
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2010-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130164228-A1 COMPOSITIONS COMPRISING GALLATES AND GALLAMIDES CUTA, PGC, GTF3C5 SERPINE1 3370/4885SYNJ2 1953/4885DYRK1A 3721/4885
US-20100137194-A1 Plasminogen Activator Inhibitor-1 Inhibitors and Methods of Use Thereof to Modulate Lipid Metabolism SERPINE1, PLAT, SERPINB1 SERPINE1 1/4885SYNJ2 3116/4885DYRK1A 4652/4885
US-20160009748-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF TO MODULATE LIPID METABOLISM SERPINE1, PLAT, SERPINB1 SERPINE1 1/4885SYNJ2 3116/4885DYRK1A 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback